HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Thursday, 8 February 2018

Cochrane Collaboration Issue 1, 2018…

….is almost complete.  The website lists reviews and protocols.  The notable reviews are……
  • Gefitinib for advanced non‐small cell lung cancer
  • Home versus in‐patient treatment for deep vein thrombosis
  • Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity

 Notable protocols are……
  • Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second‐line treatment for non–small‐cell lung cancer wild‐type or unknown status for EGFR
  • Hybrid repair versus conventional open repair for thoracic aortic arch aneurysms
  • Endovascular versus conventional open surgical repair for thoracoabdominal aortic aneurysms

Posted by at